On the topic of raising or eliminating buprenorphine dose limits, there will be a 4-hour virtual meeting on Monday, December 11, sponsored jointly by the FDA, NIDA, and SAMHSA. It will focus on the efficacy, safety, and policy issues related to high-dose buprenorphine in the context of fentanyl. There will be a series of panel discussions with nationally and internationally distinguished addiction specialists. (I don’t have the list of panelists.)
Date: December 11, 2023
Time: 1:00 PM – 5:00 PM (presumably Eastern time)
Format: Virtual – register at: https://www.zoomgov.com/
Topic: Medical need, emerging data, and barriers to accessing high-dose buprenorphine in the context of high-potency synthetic opioid exposure
Objective of the Meeting: This meeting aims to gather both quantitative and qualitative data on the need for, effectiveness, and safety of high-dose buprenorphine (24mg+) in the treatment of opioid use disorders, particularly in the emerging context of fentanyl exposure. We seek to inform federal guidelines and policies with the latest evidence and practical experiences.
